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Abstract
OBJECTIVE: To investigate the effects and mecha-
nisms of Erbanxiao solution in inhibiting tumor an-
giogenesis.
METHODS: We observed the effects and mecha-
nisms of Chinese medicines on inhibiting tumor an-
giogenesis and studied the theories and results of
treatment. Sixty patients with lung cancer were ran-
domized into two groups (n=30). Patients in the
control group were given compound Kushen injec-
tion, and patients in the treatment group were giv-
en Erbanxiao solution. The effect of Erbanxiao solu-
tion on vascular endothelium growth factor (VEGF),
basic fibroblast growth factor (bFGF), and tumor ne-
crosis factor-α (TNF-α) was observed.
RESULTS: The effective rate of the treatment group
was 60% while the control group was 36% . There
was a significant difference between the two
groups (P<0.05). VEGF, bFGF, and TNF-α levels of
the two groups were significantly different before
and after treatment (P<0.01). These Traditional Chi-
nese Medicines significantly inhibited tumor angio-
genesis, possibly by changing levels of VEGF, bFGF,
and TNF-α.
CONCLUSION: It is necessary to further explore the
potential of Traditional Chinese Medicine in the
treatment of angiogenesis in tumor patients.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Incidence of lung cancer is increasing yearly.1 While
many scholars are researching the treatment of lung
cancer, the survival rate of patients is low because of
immature differentiation and rapid growth of cancer
cells infiltrating and damaging the lung, and metastasis
of the cancer.
In this study, Erbanxiao solution was administered for
the treatment of angiogenesis in lung cancer patients.
The effect of Erbanxiao solution on vascular endotheli-
um growth factor (VEGF), basic fibroblast growth fac-
tor (bFGF), and tumor necrosis factor-α (TNF-α) was
observed.
METHODS
Diagnosis
The diagnostic criteria given in the "Textbook of Inter-
nal Medicine of National Medical Colleges" were used
for reference.2 Patients were diagnosed with non-small
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cell lung cancer by imaging, pathology, and cytology.
Traditional Chinese Medicine (TCM) differentiation
criteria given in the "Guiding principle of clinical re-
searches on new drugs of Traditional Chinese Medicine" is-
sued by the Ministry of Health of The People's Repub-
lic of China in 2002 were used for reference.3 In TCM,
lung cancer lung is defined as spleen deficiency and sta-
sis toxin stagnation.
The main symptoms include cough, sputum, chest
tightness, shortness of breath, and fatigue. Secondary
symptoms include sallow complexion, poor appetite,
pale tongue with a thin coating, and deep and thready
pulse. Patients with all of the main symptoms and one
of the secondary symptoms were diagnosed.
General data
Sixty patients meeting the diagnostic criteria were ran-
domized into observation and control groups. There
were 30 patients in the observation group, 10 males
and 20 females, aged 58-79, with average age of 67±8.
There were 30 patients in the control group, 12 males
and 18 females, aged 59-77, with average age of 68±7.
There were no significant differences between the two
groups (P>0.05). Patients were selected from Henan
Provincial People's Hospital from January 2010 to Oc-
tober 2012. According to the Tumor Node Metastasis
(TNM) staging of the International Union Against
Cancer (UICC) 4 patients were stage IIIb (T4, any N,
and M0 or any T, N3, and M0) or IV (any T, any N,
and M1).
Treatment
The treatment group received 30 mL of Erbanxiao so-
lution three times a day. Erbanxiao solution was made
of Banzhilian (Herba Scutellariae Barbatae), Chansu
(Venenum Bufonis), Shuizhi (Hirudo), Quanxie (Scor-
pio), Kunbu (Thallus Laminariae Japonicae), and Wu-
gong (Scolopendra). It was supplied by the preparation
room of Henan Provincial People's Hospital.
The control group received routine symptomatic treat-
ment and 20 mL Yanshu injection (compound Kushen
injection, made by Shanxi Zhendong Pharmaceutical
Company Ltd.) in 250 mL physiological saline IV,
once a day for 15 days as one course, for two courses.
The levels of VEGF, bFGF, and TNF-α were measured
before and after treatment with previously described
methods.5
Criterion of efficacy6
Complete remission (CR) was considered complete tu-
mor disappearance for more than one month. Partial
remission (PR) was considered the product of two max-
imum mutual vertical diameters of tumors more than
50% reduced for more than one month. Stable (SD)
was considered the product of two maximum mutual
vertical diameters of tumors not more than 50% re-
duced for more than one month. Ineffective treatment
showed no effect tumor size or the tumor size in-
creased.4
Quality of life
Karnofsky score was adopted for quality of life evalua-
tion. After treatment, a Karnofsky score increasing ≥10
was regarded as improved, decreasing >10 was thought
to be declined, and changing up or down within ten
was stable.
Detection of VEGF, bFGF, and TNF-α
Before treatment and two months after treatment, a
sample of fasting venous blood (2 mL containing no
anticoagulant) was centrifuged, and the serum was
sealed, numbered, and stored at －20℃ . The double
antibody sandwich ELISA method was used for the de-
tection of serum VEGF, bFGF, and TNF-α. The kit
was produced by American GB Company (San Francis-
co, California, the United States).
Statistical analysis
SPSS 16.0 software (SPSS, Chicago, America) package
was used for statistical analysis. Ridit analysis was used
for comparing the effective rate of tumor, t-test for
comparing the difference between the two groups, andχ2 test for comparing the increasing rate of the quality
of life. P<0.05 showed statistical difference, and P<
0.01 showed significant statistical difference.
RESULTS
Effective rate
Effective rate was 60% in the observation group and
36% in the control group. There was a significant dif-
ference between the two groups (P<0.05) (Table 1).
Changes in VEGF
The difference in VEGF levels between the two groups
before and after treatment was significant (P<0.01) (Ta-
ble 2).
Changes in bFGF
The difference in bFGF levels between the two groups
before and after treatment was significant (P<0.01) (Ta-
ble 3).
Table 1 Effective rate between the two groups before and af-
ter treatment
Group
Treatment
Control
n
30
30
CR
12
2
PR
15
10
SD
3
18
Effective rate (%)
90a
40
Notes: control group was given compound Kushen injection,
treatment group was given Erbanxiao solution. CR: complete
remission; PR: partial remission; SD: stable. Compared with the
control group, aP<0.05.
Table 2 VEGF levels between the two groups (pg/mL)
Group
Treatment
Control
n
30
30
Before
treatment
557±124
553±123
After
treatment
245±98
455±115
Difference
321±5a
101±11
Notes: control group was given compound Kushen injection,
treatment group was given Erbanxiao solution. Compared with
the control group, aP<0.01.
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Changes in TNF-α
The difference in TNF-α levels between the two
groups before and after treatment was significant (P<
0.01) (Table 4).
Changes in quality of life
There was no significant difference in the improve-
ment of quality of life between the two groups, but the
increased rate of stability was better in the observation
group than in the control group. (Table 5)
DISCUSSION
According to TCM, the etiology of lung cancer is that
weakness of Yuan-source Qi emotional depression, in-
vasion of external pathogenic factors, improper diet,
and overwork, cause the retention of phlegm and
blood stasis. This stasis and phlegm is then trans-
formed into fire and toxins. Phlegm and blood stasis
combine into lumps and obstruct the Qi circulation of
meridians and collaterals. Deficient anti-pathogenic Qi
fails to control the growth of lumps. According to the
WHO, the mortality rate of lung cancer is increasing,
and is the highest of all malignant tumors.8
Erbanxiao solution functions to clear heat, remove tox-
ins, soften lumps, dissolve phlegm, and activate blood
circulation. Banzhilian (Herba Scutellariae Barbatae)
and Chansu (Venenum Bufonis) are the principal ingre-
dients for clearing heat and removing toxins in resist-
ing cancers. Shuizhi (Hirudo), Quanxie (Scorpio), and
Kunbu (Thallus Laminariae Japonicae) are the adju-
vants to soften lumps, remove toxins, and dissolve
phlegm. Wugong (Scolopendra) is for removing blood
stasis of the meridians and collaterals.
Heat-clearing and detoxifying drugs have strong antivi-
ral activity9 and are effective in inhibiting the prolifera-
tion and metastasis of tumor cells by inducing apopto-
sis, differentiation, and reversion. They are able to im-
prove immune function, regulate cell signal transduc-
tion, resist cellular mutations, and inhibit angiogenesis
and drug-resistance. Therefore, heat-clearing drugs can
be effective antitumor agents. In addition, heat-clear-
ing and detoxifying drugs can degrade endotoxins and
oppose exotoxins, excite the pituitary-adrenocortical
system, inhibit inflammatory reactions, inhibit the syn-
thesis and release of some inflammatory mediators, in-
hibit a variety of allergies, and inhibit allergic media re-
lease and resist its effects. For example, Banzhilian (Her-
ba Scutellariae Barbatae), Shancigu (Pseudobulbus
Cremastrae), Chuanxinlian (Herba Andrographis Panicu-
latae), and Baihuasheshecao (Herba Hedyotidis) can in-
hibit the proliferation and metastasis of tumor cells, en-
hance the effect of chemotherapeutic drugs, and im-
prove immune function.9,10
Our results show that the TCM, Erbanxiao solution,
can inhibit the expression of metalloproteases, disturb
the interaction of endotheliocytes and the extracellular
matrix, and prevent the formation of the tumor vascu-
lar net.11,12
VEGF, also known as vascular permeability factor
(VPF), is a specific heparin-binding growth factor of
vascular endothelial cells. It can induce angiogenesis in
vivo,13,14 directly act on endothelial cells to promote pro-
liferation, and increase vascular permeability. Erbanx-
iao solution can inhibit the production of VEGF and
decrease serum VEGF, thereby inhibiting tumor angio-
genesis.
As a signal of transmission development, bFGF can
promote the polypeptides for division of the mesoder-
mal and neuroectodermal cells. Because it is an impor-
tant factor in the control of vascular formation,15,16 it
promotes angiogenesis. In vitro, bFGF can stimulate
the proliferation and migration of cells and induce plas-
minogen activator and collagenase activity. It also has a
high affinity for heparin.17,18
Erbanxiao solution can inhibit the production of
VEGF and bFGF in tumor cells and decrease the level
of serum VEGF and bFGF, inhibiting angiogenesis. Er-
banxiao also induces TNF-α production. TNF-α is
produced mainly by the activation of monocytes or
macrophages. TNF-α kills and inhibits tumor cells,19
promotes phagocytosis of neutrophils, resists infection,
causes fever, induces the synthesis of protein in liver
cells in the acute stage, promotes the differentiation of
myeloid leukemia cells to macrophages, and enhances
cell proliferation and differentiation. It is an important
inflammatory factor and participates in some patholog-
Table 3 bFGF levels between the two groups (pg/mL)
Group
Treatment
Control
n
30
30
Before
treatment
18.6±2.1
17.0±0.2
After
treatment
2.4±1.8
13.0±0.2
Difference
12.0±0.3a
3.1±0.0
Notes: control group was given compound Kushen injection,
treatment group was given Erbanxiao solution. Compared with
the control group, aP<0.01.
Table 4 TNF-α levels between the two groups (pg/mL)
Group
Treatment
Control
n
30
30
Before
treatment
27.5±2.4
28.0±6.3
After
treatment
35.2±3.4
28.0±6.1
Difference
8.2±3.8a
0.2±1.5
Notes: control group was given compound Kushen injection,
treatment group was given Erbanxiao solution. Compared with
the control group, aP<0.01.
Group
Treatment
Control
n
30
30
Improved
1
2
Declined
8
11
Stable
21
17
Increased rate of stability (%)
73.33
63.33
Table 5 Improvement in quality of life between the two groups
Notes: control group was given compound Kushen injection, treatment group was given Erbanxiao solution.
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ical injuries of autoimmune diseases.
The differences in VEGF, bFGF, and TNF-α levels be-
fore and after treatment were statistically significant (P<
0.01) between the observation and control groups. The
decrease in serum VEGF and bFGF levels in the obser-
vation group was greater than in the control group,
and the production of TNF-α in the observation
group was greater than in the control group, suggesting
that Erbanxiao solution was effective in treating blood
vessel hyperplasia in cancer.
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